Making every pregnancy around the world safer
Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA medicine for preterm preeclampsia. Founded in 2020 and headquartered in Concord, MA, Comanche's mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia — a life-threatening pregnancy complication affecting millions of women worldwide. The EMA granted Orphan Drug Designation for CBP-4888 in 2025.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account